Prospects and limitations of T cell receptor gene therapy.

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Ultra-sensitive detection of rare T cell clones. J Immunol Methods (2011) 1.64

Retracted Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Adv Hematol (2015) 1.49

CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. J Immunol (2014) 0.88

The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells. PLoS One (2012) 0.87

Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B. J Transl Med (2011) 0.82

Molecular characterization of T cell receptor beta variable in the peripheral blood T cell repertoire in subjects with active tuberculosis or latent tuberculosis infection. BMC Infect Dis (2013) 0.78

Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78

Genetic engineering of T-cell receptors: TCR takes to titin. Blood (2013) 0.76

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunol Immunother (2013) 0.76

Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins. Nucleic Acid Ther (2014) 0.75

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity. Oncoimmunology (2013) 0.75

Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92

Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54

Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47

Antigen bias in T cell cross-priming. Science (2004) 1.82

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78

The cancer antigenome. EMBO J (2012) 1.78

Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77

Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science (2009) 1.70

Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B. Blood (2005) 1.66

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61

STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol (2005) 1.57

One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54

Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53

Adoptive transfer of T-cell immunity. Trends Immunol (2002) 1.50

Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42

High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40

Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39

Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B. Eur J Immunol (2008) 1.36

Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proc Natl Acad Sci U S A (2011) 1.35

Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33

Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25

T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24

MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24

Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19

Generation of T cell help through a MHC class I-restricted TCR. J Immunol (2006) 1.15

Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion (2012) 1.15

Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 1.14

Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11

Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol (2007) 1.10

Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood (2008) 1.08

TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08

T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med (2010) 1.07

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07

Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 1.06

Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol (2009) 1.06

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04

High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03

Requirements for effective antitumor responses of TCR transduced T cells. J Immunol (2008) 1.02

Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01

CD8+ T cell tolerance and cancer immunotherapy. J Immunother (2003) 1.01

Specificity and affinity motifs for Grb2 SH2-ligand interactions. Proc Natl Acad Sci U S A (2002) 1.01

The descent of memory T cells. Ann N Y Acad Sci (2011) 1.01

High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00

TCR repertoires of intratumoral T-cell subsets. Immunol Rev (2014) 1.00

Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells. Hum Immunol (2005) 0.99

TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother (2009) 0.99

Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest (2013) 0.99

Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol (2004) 0.97

Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2005) 0.97

In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol (2007) 0.96

Class I major histocompatibility complexes loaded by a periodate trigger. J Am Chem Soc (2009) 0.95

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol (2008) 0.94

Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine (2008) 0.94

Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol (2009) 0.92

T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol (2011) 0.90

Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology (2002) 0.90

Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol (2013) 0.89

The impact of self-tolerance on the polyclonal CD8+ T cell repertoire. J Immunol (2004) 0.88

UV-induced ligand exchange in MHC class I protein crystals. J Am Chem Soc (2009) 0.88

Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 0.87

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res (2004) 0.87

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol (2002) 0.86

Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur J Immunol (2013) 0.84

Long-term functionality of TCR-transduced T cells in vivo. J Immunol (2008) 0.84

Developmental origin of pre-DC2. Hum Immunol (2002) 0.83

Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother (2007) 0.83

Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol (2002) 0.82

HLA micropolymorphisms strongly affect peptide-MHC multimer-based monitoring of antigen-specific CD8+ T cell responses. J Immunol (2013) 0.81

Technologies for MHC class I immunoproteomics. J Proteomics (2010) 0.81

Immunotherapeutic strategies: the melanoma example. Immunotherapy (2009) 0.79

T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies. Hum Gene Ther (2011) 0.79

Development of a hypersensitive periodate-cleavable amino acid that is methionine- and disulfide-compatible and its application in MHC exchange reagents for T cell characterisation. Chembiochem (2013) 0.78

Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood (2007) 0.78

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Cancer Res (2008) 0.78

An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. Front Immunol (2013) 0.78

Intradermal vaccination by DNA tattooing. Methods Mol Biol (2014) 0.77

Vaccine leads to memory loss. Nat Med (2007) 0.77

Microbead-assisted retroviral transduction for clinical application. Hum Gene Ther (2010) 0.76

Tumors hijack fetal enzyme, escape killer T cells. Nat Med (2003) 0.75

Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2017) 0.75

Gene transfer of MHC-restricted receptors. Methods Mol Med (2005) 0.75

Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma. Nat Med (2016) 0.75